A new study published in Frontiers of Engineering Management presents a comprehensive evaluation system to assess innovation ...

Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

CND Life Sciences, Inc. (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and ...

Viking Therapeutics witnessed a significant boost in its share price following the release of compelling data from a ...

VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome SAN DIEGO, Nov. 6, 2025 /PRNewswire/ -- Viking ...

It is a great choice for studying large volumes of information, such as website data or survey results. Sweetviz creates easy-to-read and detailed reports for datasets. It shows comparisons between ...

In analyzing dozens of AI PoCs that sailed on through to full production use — or didn’t — six common pitfalls emerge.

The biopharmaceutical sector is closely monitoring Viking Therapeutics as compelling new clinical results for its obesity ...

IIT Delhi’s 6-month programme offers faculty-led, hands-on training in Data Science, ML, Deep Learning and Generative AI, ending with a valuable certificate.

Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% ...

Verrica Pharmaceuticals (VRCA) announced the presentation of new data from its Phase 2 study evaluating VP-315, a novel oncolytic peptide ...